Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.11 Bil PE Ratio: 0 PB Ratio: 24.80 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 10:40PM GMT
Release Date Price: $62.95 (+3.84%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good afternoon, everybody. Thanks for joining us at the Bank of America Merrill Lynch Healthcare conference. I'm Tazeen Ahmad. I am the Senior (inaudible) biotech analyst here at BAML. It's my pleasure to present the next company at our conference, Ultragenyx Pharmaceuticals. Presenting for Ultragenyx today, to my right is Shalini Sharp, Chief Financial Officer. Shalini, thanks for joining us. And Shalini's going to give you a quick introduction to Ultragenyx with a few slides, and then we'll switch over to Q&A. And if anyone in the audience has a question at any time, just raise your hand and we can take your question. So, with that, I'll turn it over to you, Shalini.

Shalini Sharp
Ultragenyx Pharmaceutical Inc. - CFO & Executive VP

Thank you. Thank you to Bank of America, and to you for hosting us today, and to everyone who came to watch. I'll just speak for a couple minutes, and then we'll have a conversation.

So just a little bit of background on Ultragenyx. We are now 9 years old,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot